Navigation Links
UQ research heralds vaccine technology breakthrough

Respiratory syncytial virus (RSV) infection is a widespread infant illness that has been linked to asthma and can be deadly but may be curable by the development of this new vaccine technology by the Sir Albert Sakzewski Virus Research Centre and The University of Queensland's Faculty of Biological and Chemical Sciences.

Research centre director Professor Robert Tindle said RSV cost millions of dollars a year in health care in Australia and billions in the United States. It can lead to severe and lifethreatening lower respiratory tract infection or bronchiolitis.

About one in 1000 die from the illness. However, the vaccine that is being developed is expected to treat the illness in infected people as well as prevent against it.

Those most at risk from RSV are children aged two and under, especially those with weak respiratory symptoms, elderly people and the immunocompromised, such as people with HIV or those who have weakened immune systems due to treatments such as chemotherapy.

"Benefits of the vaccine will include a huge saving in health care costs," Professor Tindle said.

"(It will also) relieve the burden of worry on thousands of parents who every year go through all kinds of angst because their young children are going into hospital with very worrying symptoms and it would prevent the death of the children who succumb to it and die."

With preclinical modelling in mice having been encouraging, Professor Tindle said clinical trials were forthcoming, leading the way to the vaccine becoming available in the clinic. He hoped it would become one of the vaccines given to all infants in their first three months of life.

The mature paediatric market for an RSV vaccine has been estimated at approximately US$800 million (LeadDiscovery Ltd, 2004).

Professor Tindle said the importance of the research project was double-barrelled because, along with helping children, it included forming a new type of vac cine. The research group has developed a "recombinant" vaccine using the existing Hepatitis B vaccine to carry the RSV peptides.

"Hepatitis B surface antigen forms virus-like particles, which are the vaccine used for Hepatitis B vaccine all around the world," Professor Tindle said.

"We're taking advantage of that to piggyback, if you like, the respiratory syncytial virus peptides into the vaccine."

He hoped the vaccine would ultimately be able to protect people against both diseases in the one shot and, even better, the recombinant vaccine model could potentially be used for most infectious diseases and some cancers, Professor Tindle said.

Playing a key role in the research group is international expert on recombinant vaccines, Dr Scott Thomson. Professor Tindle said gaining Dr Thomson's expertise was a coup for the project.

"If anyone's going to get the (vaccine) it's going to be Scott," Professor Tindle said.


Source:Research Australia

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:

(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology: